Saeho Chong, PhD
Chief Executive Officer
Dr. Saeho Chong brings more than 25 years of senior management experience, including more than a decade of strategic development in the pharmaceutical industry. He most recently served as Vice President, Early Development at Alnylam Pharmaceuticals, where he had a significant track record of success in R&D. Previously, he served in roles of increasing responsibility and leadership at Bristol-Myers Squibb and Millennium (Takeda Oncology). He also held a prior position in the U.S. Food and Drug Administration’s (FDA) Office of Clinical Pharmacology and was a professor of Pharmaceutical Sciences, College of Pharmacy at Seoul National University.
Dr. Chong received his B.S. and Ph.D. in Pharmaceutics at the esteemed School of Pharmacy of the State University of New York at Buffalo. He received post-graduate training under the guidance of Dr. HL Fung at SUNY Buffalo and is currently an Adjunct Associate Professor of Pharmaceutical Sciences at SUNY Buffalo. He has held editorial board positions of the American Association of Pharmaceutical Scientists Journal, Drug Metabolism and Pharmacokinetics, Archives of Pharmacal Research, and the Journal of Pharmaceutical Investigation, and has authored more than 90 publications in peer-reviewed journals.
Seong H. Jang, PhD
Chief Operating Officer
Dr. Seong H. Jang brings a deep expertise in clinical pharmacology, having held considerable positions of increasing responsibility at FDA for nearly 20 years. His experience includes leadership roles in the Division of Infectious Disease Pharmacology, Office of Clinical Pharmacology, Center for Drug Evaluation and Research. He and his team contributed to the approval of an impressive portfolio of new drug products in multiple therapeutic areas, including transplant, special pathogen and anti-infectives. He is widely recognized both internally and externally for his expertise and collaboration. Further, his contributions include serving as a cross disciplinary team leader in several NDA reviews and as an acting deputy division director for the Office of Study Integrity and Surveillance.
Dr. Jang earned his Ph.D. in biopharmaceutics from the College of Pharmacy at Ohio State University with focus in pharmacokinetics and pharmacodynamics and subsequently as a research fellow. He received his bachelor’s and master’s degrees from the College of Pharmacy at Seoul National University and has published numerous peer-reviewed articles and has often presented at scientific organizations such as the Clinical Trials Transformation Initiative, National Health Institutes, and the American Society for Microbiology.
Chief People Officer
Jenny Gizzi joined Elevar Therapeutics as Chief People Officer in December 2021 and brings more than 20 years of human resources experience in the biopharmaceutical sector. As Chief People Officer, Jenny is responsible for overseeing Elevar’s human resources function, including talent acquisition and administration, leadership development, compensation and benefits, and diversity and inclusion.
Prior to joining Elevar, Jenny served as Vice President of Human Resources and Talent Acquisition at Arena Pharmaceuticals, Inc. where she was responsible for all people processes, workforce planning, recruitment, compliance, employee relations, and communications.
Prior to her role at Arena Pharmaceuticals, Jenny was Vice President and Head of Human Resources and Site Operations (IT & Facilities) at Mirati Therapeutics. Formerly, she served as Head of Strategy & Operations, Business Insights and Analytics at Bristol-Myers Squibb, where she led the Celgene acquisition and integration efforts. Throughout her eight-year tenure at Bristol-Myers Squibb, she also served as Head of Human Resources, supporting early Oncology Research sites, and Head of Global Talent for European Markets, Australia, and Canada where she oversaw global talent strategy and planning for eight markets and 13 countries.
She has held various additional senior people-centric roles within life sciences companies and regularly speaks at global conferences sharing best practices and industry insights. Jenny received her certificate in Human Resource Management from the University of California San Diego, and she holds a BA in Corporate Communications from Fairleigh-Dickinson University in New Jersey.
Chief Commercial Officer
Paul Friel brings more than 30 years of experience in the pharmaceutical industry, including leadership positions in multi-national corporations and biotech companies. Mr. Friel has launched over 20 products, including 5 that achieved over 1 billion in sales, been an early leadership employee in 5 start-ups, and led Business Development for multiple large transitions and raises. He most recently served as Chief Commercial Officer of Beyond Spring, Inc. (NASDAQ: BYSI). Previously, he served in roles of increasing responsibility and leadership at TAP/Takeda where he served as President and General Manager at Takeda Canada.
Mr. Friel holds an MBA from the University of Kansas and a Bachelor of Business degree from Kansas State University.